We investigated factors that physicians consider of most importance in the selection of second line tyrosine kinase inhibitors treatments (TKIs) in chronic myeloid leukemia patients (CML).
Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients / Breccia, Massimo; Baccarani, Michele; Rosti, Gianantonio; Cottone, Francesco; Cannella, Laura; Guilhot, François; Vignetti, Marco; Efficace, Fabio. - In: HEALTH AND QUALITY OF LIFE OUTCOMES. - ISSN 1477-7525. - 15:1(2017), p. 204. [10.1186/s12955-017-0788-4]
Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients
Cottone, Francesco;Cannella, Laura;Vignetti, Marco;Efficace, Fabio
2017
Abstract
We investigated factors that physicians consider of most importance in the selection of second line tyrosine kinase inhibitors treatments (TKIs) in chronic myeloid leukemia patients (CML).File allegati a questo prodotto
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
